MinervaX

Biotech · DK

Biotech developing a prophylactic vaccine against Group B Streptococcus (GBS).

Founders

Gunnar Lindahl (Sweden · ♂) — A Lund University microbiology professor whose research identified protective surface proteins of Group B Streptococcus, he spun that science out into MinervaX in 2010 to develop a GBS vaccine.
Thomas Areschoug (Sweden · ♂) — A Lund University researcher who worked with Lindahl on the GBS vaccine candidate, he co-founded MinervaX to commercialize the discovery.

Shares the most investors with (number = shared investors):

Create a free EquityFlow account to see MinervaX's 3 funding rounds, 12 investors, 12 similar companies.